IP Library Patent Application 15061416
Patent Application
App. No. 15/061,416

PROCESS FOR PREPARING OXYCODONE COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/061,416
Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims (40)

1 - 79 . (canceled)

80 . A process for preparing an oxycodone active pharmaceutical ingredient comprising:

dissolving an oxycodone composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone and a first amount of 14-hydroxycodeinone to form a solution;

exposing the solution to conditions that affect acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone; and

isolating an oxycodone active pharmaceutical ingredient comprising a second amount of 14-hydroxycodeinone by a process comprising crystallization, the second amount of 14-hydroxycodeinone being lower than the first amount of 14-hydroxycodeinone.

81 . The process of claim 80 , wherein the conditions reduce the rate of dehydration of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone.

82 . The process of claim 81 , wherein at least some of the 8α,14-dihydroxy-7,8-dihydrocodeinone is dehydrated to the 14-hydroxycodeinone during the process.

83 . The process of claim 82 , comprising preferentially removing at least some of the 14-hydroxycodeinone from the solution.

84 . The process of claim 80 , wherein the solution comprises an alcohol.

85 . The process of claim 84 , wherein the alcohol comprises isopropyl alcohol.

86 . The process of claim 84 , wherein the solution comprises a mixture comprising an alcohol and water.

87 . The process of claim 85 , wherein the solution comprises a mixture comprising isopropyl alcohol and water.

88 . The process of claim 80 , wherein the solution comprises an acid.

89 . The process of claim 88 , wherein the acid is formic acid.

90 . The process of claim 80 , wherein the process is for preparing an oxycodone hydrochloride salt active pharmaceutical ingredient.

91 . The process of claim 89 , wherein the oxycodone hydrochloride salt active pharmaceutical ingredient comprises less than 100 ppm of 14-hydroxycodeinone.

92 . The process of claim 91 , wherein the oxycodone hydrochloride salt active pharmaceutical ingredient comprises 1 ppm or more 14-hydroxycodeinone.

93 . A process for preparing an oxycodone active pharmaceutical ingredient comprising:

dissolving an oxycodone composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone and a first amount of 14-hydroxycodeinone to form a solution;

exposing the solution to conditions that affect acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone; and

isolating an oxycodone active pharmaceutical ingredient comprising a decreased amount of 14-hydroxycodeinone by a process comprising crystallization.

94 . The process of claim 93 , wherein the conditions reduce the rate of dehydration of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone.

95 . The process of claim 94 , wherein at least some of the 8α,14-dihydroxy-7,8-dihydrocodeinone is dehydrated to the 14-hydroxycodeinone during the process.

96 . The process of claim 95 , wherein the solution comprises a catalyst.

97 . The process of claim 93 , wherein the solution comprises an alcohol.

98 . The process of claim 93 , wherein the decreased amount is less than 100 ppm.

99 . The process of claim 98 , wherein the alcohol comprises isopropyl alcohol.

100 . The process of claim 93 , wherein the solution comprises an acid.

101 . The process of claim 100 , wherein the acid is formic acid.

102 . The process of claim 93 , wherein the process is for preparing an oxycodone hydrochloride salt active pharmaceutical ingredient.

103 . The process of claim 102 , wherein the oxycodone hydrochloride salt active pharmaceutical ingredient comprises less than 100 ppm of 14-hydroxycodeinone.

104 . The process of claim 103 , wherein the oxycodone hydrochloride salt active pharmaceutical ingredient comprises 1 ppm or more 14-hydroxycodeinone.

105 . A process for preparing an oxycodone active pharmaceutical ingredient comprising:

adding an alcohol to a solution comprising oxycodone, 8α,14-dihydroxy-7,8-dihydrocodeinone and a first amount of 14-hydroxycodeinone; and

crystallizing an oxycodone active pharmaceutical ingredient comprising a second amount of 14-hydroxycodeinone;

wherein the second amount of 14-hydroxycodeinone is lower than the first amount of 14-hydroxycodeinone.

106 . The process of claim 105 , wherein the addition of alcohol affects an acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone.

107 . The process of claim 105 , wherein the oxycodone active pharmaceutical ingredient is an oxycodone salt active pharmaceutical ingredient.

108 . The process of claim 107 , wherein the oxycodone salt active pharmaceutical ingredient is an oxycodone hydrochloride salt active pharmaceutical ingredient.

109 . The process of claim 108 , wherein the oxycodone hydrochloride salt active pharmaceutical ingredient comprises less than 100 ppm of 14-hydroxycodeinone.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048936/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: CHAPMAN, ROBERT; RIDER, LONN S.; HONG, QI; KYLE, DONALD; KUPPER, ROBERT
To: EURO-CELTIQUE S.A.
Reel/Frame 040033/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: EURO-CELTIQUE S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 040034/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; THE P.F. LABORATORIES, INC.; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
Reel/Frame 040034/0442 →